Epitome Therapeutics: €4 million funding for next-generation epigenome editing platform
Epitome Therapeutics has launched with €4 million in total funding to advance CADENCE, its next-generation epigenome editing platform designed to precisely regulate gene expression without altering DNA. The EMBL spin-off aims to develop new therapies for rare and metabolic diseases.
Epitome Therapeutics has announced its launch with €4 million in total funding, comprising an oversubscribed €2 million pre-seed financing round and €2 million in non-dilutive grant funding. The investment round was co-led by XISTA Science Ventures and Caesar Ventures, with participation from Navec Venture Holding GmbH. Additional funding was provided through grants from AWS and the Austrian Research Promotion Agency (FFG). :contentReference[oaicite:0]{index=0}
The proceeds will be used to advance the company’s development programmes toward drug candidate nomination, further develop the CADENCE platform and expand the scientific and operational team. :contentReference[oaicite:1]{index=1}
Founded in 2025 by Dr. Guido Gualdoni and Dr. Jamie Hackett as a spin-off from EMBL Rome, Epitome Therapeutics is developing a therapeutic approach based on the precise regulation of gene expression. Unlike conventional gene-editing technologies that switch genes on or off, the CADENCE platform is designed to fine-tune gene activity to therapeutically meaningful levels without modifying the underlying DNA sequence. :contentReference[oaicite:2]{index=2}
According to the company, the platform combines engineered epigenetic effectors in a modular architecture to provide durable, context-dependent gene activation with improved precision, flexibility and safety. Initial therapeutic applications focus on diseases driven by dysregulated gene activity, including rare and metabolic disorders. :contentReference[oaicite:3]{index=3}
“Completing an oversubscribed financing is a strong endorsement of both our team and the potential of the CADENCE platform,” said co-founder and CEO Dr. Guido Gualdoni. Co-founder and CSO Dr. Jamie Hackett added that many diseases require precise adjustment of gene dosage rather than simply switching genes on or off, making controlled gene activation a potentially new therapeutic modality. :contentReference[oaicite:4]{index=4}
Kontakt
Epitome Therapeutics
Dr. Guido Gualdoni, CEO
E-Mail: office@epitome-tx.com
Media Contact
MC Services AG
Dr. Cora Kaiser, Dr. Johanna Kobler
Telefon: +49 89 210 228 0
E-Mail: epitome-tx@mc-services.eu